The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://allenkllm417048.bloggosite.com/46361244/retatrutide-vs-tirzepatide-a-comparative-analysis